Date: 2014-10-13
Type of information: Clinical research agreement
Compound: Opdivo® (nivolumab) and Imbruvica® (ibrutinib)
Company: BMS (USA - NY) Janssen Research & Development - J&J (USA - NJ) Pharmacyclics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism: tyrosine kinase inhibitor/Bruton's tyrosine kinase inhibitor/immune checkpoint inhibitor/monoclonal antibody. Opdivo® (nivolumab) is an investigational, fully-human PD-1 (programmed death-1) immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells
Imbruvica® (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells. IMBRUVICA blocks signals that tell malignant B cells to multiply and spread uncontrollably.
Disease: non-Hodgkin Lymphoma
Details: * On October 13, 2014, BMS, Pharmacyclics and Janssen Research & Development have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of BMS investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in combination with Imbruvica® (ibrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining Opdivo® and Imbruvica® as a potential treatment option for patients with non-Hodgkin lymphoma (NHL). The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
Financial terms:
Latest news:
